183 related articles for article (PubMed ID: 9892173)
1. Candesartan: a new-generation angiotensin II AT1 receptor blocker: pharmacology, antihypertensive efficacy, renal function, and renoprotection.
Morsing P
J Am Soc Nephrol; 1999 Jan; 10 Suppl 11():S248-54. PubMed ID: 9892173
[TBL] [Abstract][Full Text] [Related]
2. Candesartan cilexetil: a review of its preclinical pharmacology.
Nishikawa K; Naka T; Chatani F; Yoshimura Y
J Hum Hypertens; 1997 Sep; 11 Suppl 2():S9-17. PubMed ID: 9330999
[TBL] [Abstract][Full Text] [Related]
3. Candesartan cilexetil: an angiotensin II receptor blocker.
Stoukides CA; McVoy HJ; Kaul AF
Ann Pharmacother; 1999 Dec; 33(12):1287-98. PubMed ID: 10630830
[TBL] [Abstract][Full Text] [Related]
4. Pharmacologic properties of candesartan cilexetil--possible mechanisms of long-acting antihypertensive action.
Inada Y; Ojima M; Kanagawa R; Misumi Y; Nishikawa K; Naka T
J Hum Hypertens; 1999 Jan; 13 Suppl 1():S75-80. PubMed ID: 10076925
[TBL] [Abstract][Full Text] [Related]
5. [Candesartan cilexetil: pharmacological properties and protective effects against organ damage of a novel nonpeptide angiotensin II-receptor antagonist].
Inada Y; Naka T
Nihon Yakurigaku Zasshi; 2000 Mar; 115(3):151-60. PubMed ID: 10876800
[TBL] [Abstract][Full Text] [Related]
6. In vivo inhibition of angiotensin receptors in the rat kidney by candesartan cilexetil: a comparison with losartan.
Fabiani ME; Dinh DT; Nassis L; Casley DJ; Johnston CI
Am J Hypertens; 2000 Sep; 13(9):1005-13. PubMed ID: 10981551
[TBL] [Abstract][Full Text] [Related]
7. [Pharmacological profiles of candesartan cilexetil (TCV-116)].
Inada Y
Nihon Rinsho; 1999 May; 57(5):1130-6. PubMed ID: 10361446
[TBL] [Abstract][Full Text] [Related]
8. Differences among angiotensin II type 1 receptor blockers: characteristics of candesartan cilexetil.
Unger T
Blood Press Suppl; 2000; 1():14-8. PubMed ID: 11059630
[TBL] [Abstract][Full Text] [Related]
9. Candesartan cilexetil: an update of its use in essential hypertension.
Easthope SE; Jarvis B
Drugs; 2002; 62(8):1253-87. PubMed ID: 12010090
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetic-pharmacodynamic interactions of candesartan cilexetil and losartan.
Azizi M; Chatellier G; Guyene TT; Ménard J
J Hypertens; 1999 Apr; 17(4):561-8. PubMed ID: 10404959
[TBL] [Abstract][Full Text] [Related]
11. Newly emerging pharmacologic differences in angiotensin II receptor blockers.
Oparil S
Am J Hypertens; 2000 Jan; 13(1 Pt 2):18S-24S. PubMed ID: 10678284
[TBL] [Abstract][Full Text] [Related]
12. Preserving target-organ function with candesartan cilexetil in patients with hypertension.
Zannad F
Blood Press Suppl; 2000; 1():36-9. PubMed ID: 11059635
[TBL] [Abstract][Full Text] [Related]
13. Candesartan cilexetil: a new, long-acting, effective angiotensin II type 1 receptor blocker.
Sever P
J Hum Hypertens; 1997 Sep; 11 Suppl 2():S91-5. PubMed ID: 9331018
[TBL] [Abstract][Full Text] [Related]
14. Effects of an acute dose of 16 mg candesartan cilexetil on systemic and renal haemodynamics in hypertensive patients.
Fridman K; Andersson OK; Wysocki M; Friberg P
J Hum Hypertens; 1997 Sep; 11 Suppl 2():S43-4. PubMed ID: 9331005
[No Abstract] [Full Text] [Related]
15. Significance of angiotensin type 1 receptor blockade: why are angiotensin II receptor blockers different?
Unger T
Am J Cardiol; 1999 Nov; 84(10A):9S-15S. PubMed ID: 10588089
[TBL] [Abstract][Full Text] [Related]
16. Long-acting blood pressure reduction by candesartan cilexetil in patients with hypertension.
Bönner G; Fuchs W
Curr Med Res Opin; 2005 Jun; 21(6):935-40. PubMed ID: 15969893
[TBL] [Abstract][Full Text] [Related]
17. Achieving quality 24-h blood pressure control with candesartan cilexetil.
Meredith P
Blood Press Suppl; 2000; 1():23-6. PubMed ID: 11059632
[TBL] [Abstract][Full Text] [Related]
18. Improving antihypertensive efficacy while maintaining placebo-like tolerability.
Sever PS
Blood Press Suppl; 2000; 1():19-22. PubMed ID: 11059631
[TBL] [Abstract][Full Text] [Related]
19. Effects of the insurmountable angiotensin AT1 receptor antagonist candesartan and the surmountable antagonist losartan on ischemia/reperfusion injury in rat hearts.
Wang QD; Sjöquist PO
Eur J Pharmacol; 1999 Sep; 380(1):13-21. PubMed ID: 10513555
[TBL] [Abstract][Full Text] [Related]
20. Involvement of angiotensin II in cardiovascular and renal injury: effects of an AT1-receptor antagonist on gene expression and the cellular phenotype.
Kim S; Iwao H
J Hypertens Suppl; 1997 Dec; 15(6):S3-7. PubMed ID: 9493120
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
